Boehringer Ingelheim has chosen ChemAxon, a provider of chemistry software solutions and consulting services for life science research, as its provider for a chemistry software platform for multiple applications across R&D, supporting in-house activities and work with external collaboration partners.

ChemAxon technology will be used to store, search, calculate and visualize chemical entities, properties and reactions, helping to streamline the progression from drug discovery to clinical candidate. Boehringer Ingelheim chose ChemAxon after an extensive evaluation process that built on dimensions such as ROI, performance, robustness, scalability and future development roadmap.

"The adoption of ChemAxon technology by Boehringer Ingelheim further underlines our position as the platform of choice for R&D organizations planning their next-generation systems,” said Alex Drijver, CEO of ChemAxon.

With a client list that includes all of the top 15 global pharma companies, ChemAxon continues to experience significant growth year on year.